marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q2
added 08-11-2023
vTv Therapeutics Balance Sheet 2011-2024 | VTVT
Annual Balance Sheet vTv Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-11.6 M | -12.7 M | - | 5.34 M | 14 M | 7.83 M | -40.4 M | -88 M | 34.8 M | 82.1 M | - | - |
Long Term Debt |
338 K | 492 K | - | - | 6.33 M | 15.3 M | 11.1 M | - | 36 M | 2.26 M | - | - |
Long Term Debt Current |
154 K | 184 K | 155 K | 110 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 44.9 M | 72.6 M | 152 M | 134 M | 162 M | 505 M | 232 M | - | - |
Total Current Liabilities |
7.71 M | 8.5 M | 6.39 M | 13.4 M | 18.8 M | 26.9 M | 11.4 M | 7.73 M | - | - | - | - |
Total Liabilities |
27.4 M | 10.3 M | 11 M | 58.3 M | 91.4 M | 179 M | 145 M | 170 M | 512 M | 319 M | - | - |
Deferred Revenue |
17 K | 35 K | - | 31 K | 1.75 M | 8.76 M | 21 K | 219 K | - | - | - | - |
Retained Earnings |
-266 M | -249 M | - | -234 M | -234 M | -279 M | -215 M | -196 M | -499 M | -304 M | - | - |
Total Assets |
33.2 M | 25.5 M | 14.8 M | 9.27 M | 8.56 M | 27.9 M | 54.5 M | 91.5 M | 13 M | 15.5 M | - | - |
Cash and Cash Equivalents |
12.1 M | 13.4 M | 5.75 M | 1.78 M | 1.68 M | 11.8 M | 51.5 M | 88 M | 1.38 M | 1.09 M | - | - |
Book Value |
5.84 M | 15.2 M | 3.79 M | -49 M | -82.9 M | -151 M | -90.9 M | -78 M | -499 M | -304 M | - | - |
Total Shareholders Equity |
-10.7 M | -9.74 M | -80.1 M | -49 M | -82.9 M | -151 M | -90.9 M | -78 M | -499 M | -304 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet vTv Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
256 K | 297 K | 338 K | 333 K | 388 K | 441 K | 492 K | 540 K | 587 K | 633 K | 676 K | 676 K | 676 K | 676 K | 5.04 M | 831 K | 831 K | 831 K | 15.1 M | - | - | - | - | - | - | - | 11.1 M | - | - | - | - | - | - | - | 2.11 M | 2.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.8 M | 28.4 M | 27.4 M | 27.9 M | 29.6 M | 13.9 M | 10.3 M | 8.37 M | 9.29 M | 10.4 M | 11 M | 11 M | 11 M | 11 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 22.9 M | 22.9 M | 22.9 M | 22.9 M | 7.97 M | 7.97 M | 7.97 M | 7.97 M | 73.7 M | 73.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
17 K | 17 K | 17 K | 26 K | 26 K | 35 K | 35 K | 35 K | 35 K | 35 K | 31 K | 31 K | 31 K | 31 K | 31 K | 31 K | 31 K | 31 K | 1.75 M | 1.75 M | 1.75 M | 8.75 M | 8.76 M | 8.76 M | 8.76 M | 4 K | 21 K | 21 K | 21 K | 21 K | 219 K | 219 K | 219 K | 219 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-281 M | -274 M | -266 M | -267 M | -253 M | -248 M | -249 M | -259 M | -273 M | -275 M | -290 M | -290 M | -290 M | -290 M | -234 M | -234 M | -234 M | -234 M | -234 M | -234 M | -234 M | -234 M | -279 M | -279 M | -279 M | -279 M | -215 M | -215 M | -215 M | -215 M | -196 M | -196 M | -196 M | -196 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
22.4 M | 28.8 M | 33.2 M | 35.5 M | 37 M | 20.2 M | 25.5 M | 31.4 M | 21.7 M | 16.8 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 9.27 M | 9.27 M | 9.27 M | 9.27 M | 8.56 M | 8.56 M | 8.56 M | 8.56 M | 27.9 M | 27.9 M | 27.9 M | 27.9 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 91.5 M | 91.5 M | 91.5 M | 91.5 M | 13 M | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.6 M | 18.8 M | 12.1 M | 15.3 M | 17.9 M | 12.1 M | 13.4 M | 19.6 M | 10.8 M | 8.45 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M | 1.78 M | 1.78 M | 1.78 M | 1.78 M | 1.68 M | 1.68 M | 1.68 M | 1.68 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 51.5 M | 51.5 M | 51.5 M | 51.5 M | 88 M | 88 M | 88 M | 88 M | 1.38 M | 1.38 M | - | - | 1.09 M | - | - | - | 2.12 M | - | - | - | - | - | - | - |
Book Value |
-6.4 M | 408 K | 5.84 M | 7.64 M | 7.39 M | 6.27 M | 15.2 M | 23.1 M | 12.4 M | 6.37 M | 3.79 M | 3.79 M | 3.79 M | 3.79 M | -8.84 M | -8.84 M | -8.84 M | -8.84 M | -20.4 M | -20.4 M | -20.4 M | -20.4 M | -19.6 M | -19.6 M | -19.6 M | -19.6 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 83.6 M | 83.6 M | 83.6 M | 83.6 M | -60.7 M | -60.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-25.3 M | -19.2 M | -10.7 M | -16.6 M | -8.53 M | -8.09 M | -9.74 M | -21.5 M | -47.8 M | -56.3 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | -49 M | -49 M | -49 M | -49 M | -82.9 M | -82.9 M | -82.9 M | -82.9 M | -151 M | -151 M | -151 M | -151 M | -90.9 M | -90.9 M | -90.9 M | -90.9 M | -78 M | -78 M | -78 M | -78 M | -499 M | -499 M | - | - | -304 M | - | - | - | -180 M | - | - | - | - | - | - | - |
All numbers in USD currency